Experiences and needs for work participation in employees with rheumatoid arthritis treated with anti-tumour necrosis factor therapy

被引:16
|
作者
Van der Meer, Marrit [1 ]
Hoving, Jan L. [1 ,2 ]
Vermeulen, Marjolein I. M. [1 ]
Herenius, Marieke M. J. [3 ]
Tak, Paul P. [3 ]
Sluiter, Judith K. [1 ]
Frings-dresen, Monique H. W. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, NL-1100 DE Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Res Ctr Insurance Med, NL-1100 DE Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Med, Div Clin Immunol & Rheumatol, NL-1100 DE Amsterdam, Netherlands
关键词
Rheumatoid arthritis; work; participation; qualitative study; tumour necrosis factor-alpha; QUALITY-OF-LIFE; CONCOMITANT METHOTREXATE; MONOCLONAL-ANTIBODY; DISABILITY; ADALIMUMAB; MULTICENTER; PERCEPTIONS; EMPLOYMENT; CRITERIA; OUTCOMES;
D O I
10.3109/09638288.2011.582923
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
Purpose. To investigate the experiences and needs with respect to work participation of employees with rheumatoid arthritis (RA) treated with anti-tumour necrosis factor (TNF) therapy. Method. Face-to-face interviews in 14 employees with RA on anti-TNF therapy focused on experiences, offered support and needs with respect to work participation. Results. Experiences regarding work participation varied and ranged from fatigue at work, having no job control, not being understood by the work environment or difficulty dealing with emotions as a result of interaction within the work environment. Support by health care professionals for work participation was considered important, especially concerning social or psychological issues. Advice in becoming aware of one's changes in abilities was highly appreciated, as was the availability of professional advice in times of an urgent work issue due to RA. Employees mentioned an increase in social support at work and job control as important facilitating factors for work participation. Conclusion. Although patients with RA report improvement in their work functioning after starting anti-TNF therapy, employees continue facing challenges in working life due to RA. For support concerning work participation, it is recommended that health care professionals are more aware of work-related problems in patients with RA treated with anti-TNF therapy.
引用
收藏
页码:2587 / 2595
页数:9
相关论文
共 50 条
  • [1] The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis
    Askling, Johan
    Dixon, Will
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (02) : 138 - 144
  • [2] Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
    Maria J Leandro
    [J]. Arthritis Research & Therapy, 11
  • [3] Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
    Leandro, Maria J.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2009, 11 (05)
  • [4] Anti-tumour necrosis factor a therapy in rheumatoid arthritis: an update on safety
    Hyrich, KL
    Silman, AJ
    Watson, KD
    Symmons, DPM
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) : 1538 - 1543
  • [5] The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
    Harrold, Leslie R.
    Reed, George W.
    Kremer, Joel M.
    Curtis, Jeffrey R.
    Solomon, Daniel H.
    Hochberg, Marc C.
    Greenberg, Jeffrey D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 430 - 436
  • [6] Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis
    Alcorn, Nicola
    Tierney, Ann
    Wu, Olivia
    Gilmour, Harper
    Madhok, Rajan
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (08) : 1571 - 1571
  • [7] Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy
    Winthrop, K. L.
    Furst, D. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (10) : 1735 - 1737
  • [8] Gene expression profiling of rheumatoid arthritis patients treated with anti-tumour necrosis factor
    Coenen, Marieke J. H.
    Toonen, Erik J. M.
    Batliwalla, Franak
    van Riel, Piet L. C. M.
    Kievit, Wietske
    Veltman, Joris A.
    Eijsbouts, Agnes M. M.
    Gilissen, Christian F. H. A.
    Damle, Aarti
    Scheffer, Hans
    Radstake, Timoth R. D. J.
    Gregersen, Peter K.
    Barrera, Pilar
    Franke, Barbara
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S615 - S616
  • [9] Salmonella enterica Arthritis in a Patient with Rheumatoid Arthritis Receiving Anti-tumour Necrosis Factor Therapy
    Bubonja-Sonje, M.
    Rubinic, D.
    Anic, F.
    Novak, S.
    Vuckovic, D.
    Abram, M.
    [J]. WEST INDIAN MEDICAL JOURNAL, 2013, 62 (03): : 270 - 272
  • [10] Anti-tumour necrosis factor α therapy modulates ghrelin in patients with severe rheumatoid arthritis
    Gonzalez-Gay, M. A.
    Garcia-Unzueta, M. T.
    Berja, A.
    Vazquez-Rodriguez, T. R.
    Gonzalez-Juanatey, C.
    de Matias, J. M.
    Martin, J.
    Dessein, P. H.
    Llorca, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) : 1644 - 1646